Drug Trial Radar · NCT07575308
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Jun 30, 2027
Study completion Aug 30, 2029
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- May 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 16 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
Conditions
- Von Willebrand Disease (VWD)
- Heavy Menstrual Bleeding (HMB)
Interventions
ALN-6400Drug
ALN-6400 will be administered subcutaneously (SC).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Adverse EventsTime frame: Up to Week 72
Locations
29 sites in 6 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Orange, California · Not yet recruiting
Clinical Trial Site
San Diego, California · Not yet recruiting
Clinical Trial Site
San Francisco, California · Not yet recruiting
Clinical Trial Site
Miami, Florida · Recruiting
Clinical Trial Site
Augusta, Georgia · Not yet recruiting
Clinical Trial Site
Lexington, Kentucky · Not yet recruiting
Clinical Trial Site
Chapel Hill, North Carolina · Not yet recruiting
Clinical Trial Site
Cleveland, Ohio · Not yet recruiting
Clinical Trial Site
Pittsburgh, Pennsylvania · Not yet recruiting
Clinical Trial Site
Charleston, South Carolina · Not yet recruiting
Clinical Trial Site
Bad Homburg, Germany · Not yet recruiting
Clinical Trial Site
Berlin, Germany · Not yet recruiting
Clinical Trial Site
Duisburg, Germany · Not yet recruiting
Clinical Trial Site
Frankfurt am Main, Germany · Not yet recruiting
Clinical Trial Site
Nijmegen, Netherlands · Not yet recruiting
Clinical Trial Site
Utrecht, Netherlands · Not yet recruiting
Clinical Trial Site
Stockholm, Sweden · Not yet recruiting
Clinical Trial Site
Istanbul, Turkey (Türkiye) · Not yet recruiting
Clinical Trial Site
Izmir, Turkey (Türkiye) · Not yet recruiting
Clinical Trial Site
Izmir, Turkey (Türkiye) · Not yet recruiting
Clinical Trial Site
Şahinbey, Turkey (Türkiye) · Not yet recruiting
Clinical Trial Site
Samsun, Turkey (Türkiye) · Not yet recruiting
Clinical Trial Site
Birmingham, United Kingdom · Not yet recruiting
Clinical Trial Site
Bradford, United Kingdom · Not yet recruiting
Clinical Trial Site
London, United Kingdom · Not yet recruiting
Clinical Trial Site
London, United Kingdom · Not yet recruiting
Clinical Trial Site
London, United Kingdom · Not yet recruiting
Clinical Trial Site
Oxford, United Kingdom · Not yet recruiting
Clinical Trial Site
Truro, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.